Indegene enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024
14,405———
1,1611,4001,531985
0.00.00.0403
13,244———
−1,161−1,400−1,531−582
₹550.70———
3,3583,1392,6161,832
0.0%0.0%0.0%22.0%
3.21×———
19.39×———
25.91×———
21.84×———
Reference items — trailing FY values
4,1313,5112,8392,590
683619534505
511493454429
—651442508
607607412497
—602409489
—44.330.010.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDGN₹598.95

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹14,405 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization———14,404.7
- Cash, Equiv & ST Investments985.11,530.71,400.31,160.5
+ Total Debt403.10.00.00.0
Enterprise Value———13,244.2
Net Debt (memo)-582.0-1,530.7-1,400.3-1,160.5
EV per Share———550.70
Total Capital1,832.22,615.63,138.73,358.4
Total Debt/Total Capital22.000.000.000.00
EV/Sales———3.21
EV/EBITDA———19.39
EV/EBIT———25.91
EV/Free Cash Flow———21.84
Reference Items — Trailing FY Values
Sales2,589.62,839.33,510.54,130.9
EBITDA505.4534.3619.0683.0
EBIT429.3454.1492.6511.1
Operating Cash Flow507.7441.9650.8—
Free Cash Flow497.0411.9606.5606.5
FCFF (free cash flow to the firm)488.6409.4601.9—
Capital Expenditure10.730.044.3—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.